Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
Aspirin
Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.
1 other identifier
interventional
50
1 country
1
Brief Summary
Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event. The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences. Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 16, 2011
CompletedFirst Posted
Study publicly available on registry
June 17, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedJune 21, 2011
June 1, 2011
7 months
June 16, 2011
June 20, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke
We study laboratory parameters of the first 300 mg oral dose of aspirin given, within 48 hours, after ischemic cerebral event. For all patients, two blood sampling are performed, the first, during the third hour after aspirin intake and the second during the twenty-fourth hour. Platelet reactivity is studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
1 month
Secondary Outcomes (1)
Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated
1 month
Interventions
Administration of 300 mg of aspirin, per os.
2 blood samples will be performed
Eligibility Criteria
You may qualify if:
- Adult men and women
- Ischemic stroke less than 48 hours
- Signed consent
You may not qualify if:
- Danger to prescription of aspirin (haemorrhagic risk...)
- Prescription of heparin or VKA
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hopital central
Nancy, 54035, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
June 16, 2011
First Posted
June 17, 2011
Study Start
December 1, 2010
Primary Completion
July 1, 2011
Last Updated
June 21, 2011
Record last verified: 2011-06